Previous 10 | Next 10 |
Integra LifeSciences Holdings (NASDAQ:IART) is scheduled to announce Q4 earnings results on Wednesday, February 23rd, before market open. The consensus EPS Estimate is $0.84 (flat Y/Y) and the consensus Revenue Estimate is $403.41M (+3.8% Y/Y). Over the last 2 years, IART has beaten EPS estim...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Integra LifeSciences has seen a year of consolidation with heightened valuations coming down to more normal levels. Appeal is starting to emerge again, as I currently regard shares trading at around fair value. On further dips, or following a convincing 2022 outlook, I might be wi...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Fourth quarter 2021 revenue is expected to be in a range of $404 million to $406 million, representing an increase of approximately 4% on a reported basis and an increase of approximately 8% on an organic basis compared to the prior year. Full-year 2021 revenue is expected to be in ...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
BD Announces Board of Directors for embecta, the Planned Spinoff of its Diabetes Care Business PR Newswire FRANKLIN LAKES, N.J. , Dec. 21, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, t...
The global medical devices market is growing quickly, aided by substantial investment in technological advancement and the development of smart solutions. And the growing prevalence of chronic diseases and an aging population are driving market demand. Recently, medical devices stocks Edwards...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Larry Culp finally pulled the plug on General Electric (NYSE: GE ) stock, killing the 129-year old conglomerate that created the industrial age. Source: Jonathan Weiss / Shutterstock.com Ironically, the electr...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
21.25%Change Percent:
Integra LifeSciences Holdings Corporation Company Name:
IART Stock Symbol:
NASDAQ Market:
Integra LifeSciences Holdings Corporation Website:
2024-07-30 06:30:09 ET Citigroup analyst issues SELL recommendation for IART on July 30, 2024 03:24AM ET. The previous analyst recommendation was Neutral. IART was trading at $25.42 at issue of the analyst recommendation. The overall analyst consensus : SELL. Current...
2024-07-30 06:00:06 ET Joanne Wuensch from Citigroup issued a price target of $23.00 for IART on 2024-07-30 03:24:00. The adjusted price target was set to $23.00. At the time of the announcement, IART was trading at $25.42. The overall price target consensus is at $47.00...
2024-07-29 18:00:04 ET Ryan Zimmerman from BTIG issued a price target of $22.00 for IART on 2024-07-29 16:12:00. The adjusted price target was set to $22.00. At the time of the announcement, IART was trading at $25.42. The overall price target consensus is at $51.17 with...